Roy D. Baynes - Mar 11, 2025 Form 3 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Roy D. Baynes
Stock symbol
NRIX
Transactions as of
Mar 11, 2025
Transactions value $
$0
Form type
3
Date filed
3/13/2025, 04:07 PM
Previous filing
Feb 12, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NRIX Director Stock Option (right to buy) Mar 11, 2025 Common Stock 10K $9.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested as to 1/2 of the total shares on April 1, 2024, and vests as to the remaining 1/2 of the total shares on April 1, 2025, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

Exhibit 24 - Power of Attorney